Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
The Ministry of Health, Labor and Welfare (MHLW) approved a throng of new medicines on January 22, including OrphanPacific’s sakigake-designated hereditary angioedema (HAE) treatment Orladeyo (berotralstat), which was developed by BioCryst Pharmaceuticals. A plasma kallikrein inhibitor, Orladeyo was approved for…
To read the full story
Related Article
- 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
- Yescarta Approved in Japan as 2nd CAR-T Cell Therapy
January 22, 2021
- Ono’s Cancer Cachexia Med Clears PAFSC Review after Recommendation Hold
December 14, 2020
- MHLW Panel OKs Takeda’s ALK Drug, Lynparza’s Pancreatic Cancer Use; Seikagaku’s Osteoarthritis Med Put under Continued Review
December 7, 2020
- Lilly’s Galcanezumab Clears PAFSC Review, 1st Antibody for Migraine Prevention
December 3, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review
November 2, 2020
REGULATORY
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…